Form 4 Filing for Moat Ross

This filing details transactions made by Moat Ross, Chief Operating Officer of Kiniksa Pharmaceuticals International, plc. On April 6, 2026, 2,367 Class A Ordinary Shares were disposed of at $48.58 per share, under a 10b5-1 plan. On April 7, 2026, 2,477 Restricted Share Units (RSUs) were acquired, with a transaction value of $0.0, and these RSUs represent a contingent right to receive Class A Ordinary Shares. The RSUs vest over four years. On the same day, 774 Class A Ordinary Shares were disposed of at $48.94 per share. Following these transactions, Moat Ross holds 13,732 Class A Ordinary Shares.